Salix Pharms Drug Patent Portfolio
Salix Pharms owns 6 orange book drugs protected by 48 US patents with Metozolv Odt having the least patent protection, holding only 1 patent. And Xifaxan with maximum patent protection, holding 35 patents. Given below is the list of Salix Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8247425 | Peripheral opioid receptor antagonists and uses thereof | 31 Dec, 2030 | Active |
| US10314828 | Methods of treating hepatic encephalopathy | 02 Oct, 2029 | Active |
| US8642573 | Methods of treating hepatic encephalopathy | 02 Oct, 2029 | Active |
| US8969398 | Methods of treating hepatic encephalopathy | 02 Oct, 2029 | Active |
| US8420663 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US8822490 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US9180125 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US9492445 | Peripheral opioid receptor antagonists and uses thereof | 30 Sep, 2029 | Active |
| US10335397 | Methods of treating hepatic encephalopathy | 24 Jul, 2029 | Active |
| US10709694 | Methods of treating hepatic encephalopathy | 24 Jul, 2029 | Active |
| US7928115 | Methods of treating travelers diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US8829017 | Methods of treating traveler's diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US8946252 | Methods of treating traveler's diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US9421195 | Methods of treating hepatic encephalopathy | 24 Jul, 2029 | Active |
| US9629828 | Methods of treating traveler's diarrhea and hepatic encephalopathy | 24 Jul, 2029 | Active |
| US8309569 | Methods for treating diarrhea-associated irritable bowel syndrome | 18 Jul, 2029 | Active |
| US10456384 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US10765667 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US11564912 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US11779571 | Methods for treating irritable bowel syndrome (IBS) | 26 Feb, 2029 | Active |
| US7687075 | Colonic purgative composition with soluble binding agent | 22 Jun, 2028 | Active |
| US8193196 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 02 Sep, 2027 | Active |
| US10703763 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US8518949 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US8741904 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US9271968 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations | 27 Feb, 2026 | Active |
| US7906542 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin | 01 Jun, 2025 | Active |
| US7915275 | Use of polymorphic forms of rifaximin for medical preparations | 23 Feb, 2025 | Expired |
| US7169381 | Colon cleansing compositions and methods | 01 Sep, 2024 | Expired |
| US7658914 | Colon cleansing compositions | 01 Sep, 2024 | Expired |
| US7045620 | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations | 19 Jun, 2024 | Expired |
| US7612199 | Polymorphic forms α, β, and γ of rifaximin | 19 Jun, 2024 | Expired |
| US7902206 | Polymorphic forms α, β and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8158644 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8158781 | Polymorphic forms α, β and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8835452 | Polymorphic forms α, β and γ of rifaximin | 19 Jun, 2024 | Expired |
| US8853231 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin | 19 Jun, 2024 | Expired |
| US10376584 | Stable pharmaceutical formulations of methylnaltrexone | 08 Apr, 2024 | Expired |
| US8552025 | Stable methylnaltrexone preparation | 08 Apr, 2024 | Expired |
| US9669096 | Stable pharmaceutical formulations of methylnaltrexone | 08 Apr, 2024 | Expired |
| US6861053 | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US7452857 | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US7605240 | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US7718608 | Methods of treating a subject suffering from irritable bowel syndrome | 11 Aug, 2019 | Expired |
| US7935799 | Methods of treating diarrhea caused by small intestinal bacterial overgrowth | 11 Aug, 2019 | Expired |
| US6559158 | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects | 03 Nov, 2017 | Expired |
| US6413549 | Fast-Dispersing solid oral dosage form containing coarse particles | 11 Jul, 2017 | Expired |
| US5616346 | Non-aqueous colonic purgative formulations | 18 May, 2013 | Expired |
Latest Legal Activities on Salix Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Salix Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Apr, 2024 | US8309569 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Feb, 2024 | US10765667 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Jan, 2024 | US8247425 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2024 | US9421195 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Dec, 2023 | US10703763 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Dec, 2023 | US10709694 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8193196 (Litigated) |
|
Email Notification
Critical
| 11 Oct, 2023 | US11779571 |
| Patent eGrant Notification | 10 Oct, 2023 | US11779571 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 10 Oct, 2023 | US11779571 |
| Mail Patent eGrant Notification | 10 Oct, 2023 | US11779571 |
| Recordation of Patent eGrant | 10 Oct, 2023 | US11779571 |
|
Recordation of Patent Grant Mailed
Critical
| 10 Oct, 2023 | US11779571 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Sep, 2023 | US8158781 (Litigated) |
|
Email Notification
Critical
| 21 Sep, 2023 | US11779571 |
Salix Pharms Drug Patents' Oppositions Filed in EPO
Salix Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 08, 2008, by Interquim, S.A. De C.V.. This opposition was filed on patent number EP04005541A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP09818544A | Sep, 2020 | Hollatz, Christian | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP09818544A | Sep, 2020 | Aera A/S | Granted and Under Opposition |
| EP09818544A | Aug, 2020 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP09818544A | Aug, 2020 | CMS Cameron McKenna Nabarro Olswang LLP | Granted and Under Opposition |
| EP09715020A | Dec, 2019 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP09715020A | Dec, 2019 | Lederer & Keller Patentanwälte Partnerschaft mbB | Granted and Under Opposition |
| EP09715020A | Dec, 2019 | Sandoz GmbH | Granted and Under Opposition |
| EP10184575A | Sep, 2015 | Actavis Group PTC ehf | Revoked |
| EP10184575A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP10184684A | Sep, 2015 | Actavis Group PTC ehf | Revoked |
| EP04759349A | Sep, 2015 | Actavis Group PTC ehf | Patent maintained as amended |
| EP04759349A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Patent maintained as amended |
| EP10184684A | Sep, 2015 | Fresenius Kabi Deutschland GmbH | Revoked |
| EP05004695A | Jun, 2015 | Sandoz GmbH | Revoked |
| EP03758361A | May, 2009 | Teva Pharmaceutical Industries LTD. | Opposition procedure closed |
| EP04005541A | Feb, 2008 | Interquim, S.A. De C.V. | Opposition rejected |
Salix Pharms's Family Patents
Salix Pharms drugs have patent protection in a total of 42 countries. It's US patent count contributes only to 29.5% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Salix Pharms Drug List
Given below is the complete list of Salix Pharms's drugs and the patents protecting them.
1. Metozolv Odt
Metozolv Odt is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6413549 | Fast-Dispersing solid oral dosage form containing coarse particles |
11 Jul, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metozolv Odt's drug page
2. Moviprep
Moviprep is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7169381 | Colon cleansing compositions and methods |
01 Sep, 2024
(8 months ago)
| Expired |
| US7658914 | Colon cleansing compositions |
01 Sep, 2024
(8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Moviprep's drug page
3. Osmoprep
Osmoprep is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7687075 | Colonic purgative composition with soluble binding agent |
22 Jun, 2028
(3 years from now)
| Active |
| US5616346 | Non-aqueous colonic purgative formulations |
18 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Osmoprep's drug page
4. Relistor
Relistor is protected by 9 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8247425 | Peripheral opioid receptor antagonists and uses thereof |
31 Dec, 2030
(5 years from now)
| Active |
| US8420663 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(4 years from now)
| Active |
| US8822490 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(4 years from now)
| Active |
| US9180125 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(4 years from now)
| Active |
| US9492445 | Peripheral opioid receptor antagonists and uses thereof |
30 Sep, 2029
(4 years from now)
| Active |
| US10376584 | Stable pharmaceutical formulations of methylnaltrexone |
08 Apr, 2024
(1 year, 1 month ago)
| Expired |
| US8552025 | Stable methylnaltrexone preparation |
08 Apr, 2024
(1 year, 1 month ago)
| Expired |
| US9669096 | Stable pharmaceutical formulations of methylnaltrexone |
08 Apr, 2024
(1 year, 1 month ago)
| Expired |
| US6559158 | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
03 Nov, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relistor's drug page
5. Visicol
Visicol is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5616346 | Non-aqueous colonic purgative formulations |
18 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Visicol's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Xifaxan
Xifaxan is protected by 35 patents, out of which 13 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10314828 | Methods of treating hepatic encephalopathy |
02 Oct, 2029
(4 years from now)
| Active |
| US8642573 | Methods of treating hepatic encephalopathy |
02 Oct, 2029
(4 years from now)
| Active |
| US8969398 | Methods of treating hepatic encephalopathy |
02 Oct, 2029
(4 years from now)
| Active |
| US10314828 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US10335397 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US10709694 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US7928115 | Methods of treating travelers diarrhea and hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US8829017 | Methods of treating traveler's diarrhea and hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US8946252 | Methods of treating traveler's diarrhea and hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US9421195 | Methods of treating hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US9629828 | Methods of treating traveler's diarrhea and hepatic encephalopathy |
24 Jul, 2029
(4 years from now)
| Active |
| US8309569 | Methods for treating diarrhea-associated irritable bowel syndrome |
18 Jul, 2029
(4 years from now)
| Active |
| US10456384 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US10765667 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US11564912 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US11779571 | Methods for treating irritable bowel syndrome (IBS) |
26 Feb, 2029
(3 years from now)
| Active |
| US8193196 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
02 Sep, 2027
(2 years from now)
| Active |
| US10703763 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(9 months from now)
| Active |
| US8518949 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(9 months from now)
| Active |
| US8741904 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(9 months from now)
| Active |
| US9271968 | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
27 Feb, 2026
(9 months from now)
| Active |
| US7906542 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
01 Jun, 2025
(16 days from now)
| Active |
| US7915275 | Use of polymorphic forms of rifaximin for medical preparations |
23 Feb, 2025
(2 months ago)
| Expired |
| US7045620 | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
19 Jun, 2024
(10 months ago)
| Expired |
| US7612199 | Polymorphic forms α, β, and γ of rifaximin |
19 Jun, 2024
(10 months ago)
| Expired |
| US7902206 | Polymorphic forms α, β and γ of rifaximin |
19 Jun, 2024
(10 months ago)
| Expired |
| US8158644 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
19 Jun, 2024
(10 months ago)
| Expired |
| US8158781 | Polymorphic forms α, β and γ of rifaximin |
19 Jun, 2024
(10 months ago)
| Expired |
| US8835452 | Polymorphic forms α, β and γ of rifaximin |
19 Jun, 2024
(10 months ago)
| Expired |
| US8853231 | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
19 Jun, 2024
(10 months ago)
| Expired |
| US6861053 | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(5 years ago)
| Expired |
| US7452857 | Methods of treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(5 years ago)
| Expired |
| US7605240 | Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(5 years ago)
| Expired |
| US7718608 | Methods of treating a subject suffering from irritable bowel syndrome |
11 Aug, 2019
(5 years ago)
| Expired |
| US7935799 | Methods of treating diarrhea caused by small intestinal bacterial overgrowth |
11 Aug, 2019
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xifaxan's drug page